Cannabis Dispensary Roundup: SLOCAL Roots, The Botanist, Columbia Care, Ethos Cannabis
SLOCAL Roots Opens Shop In San Luis Obispo, Plans To Launch Another California Retail Location This Fall
Columbia Care And Acreage Holdings’ Cannabis Workers In New Jersey Vote To Unionize
The United Food and Commercial Workers (UFCW) Local 360 announced that employees at Columbia Care's (OTCQX: CCHWF) Cannabist retail location and Acreage Holdings’ (OTCQX: ACRHF)&n
Curaleaf, Columbia Care, TerrAscend And Others Ready To Roll In New Jersey
New Jersey legal recreational cannabis sales finally started. Now, the question is: Who will celebrate more? Consumers or marijuana operators?
These 7 New Jersey Cannabis Operators Are Ready And Waiting To Kick Off Rec Sales
New Jersey legal recreational cannabis sales will launch on April 21, state officials announced Friday.
New Jersey Police Officers Can Legally Consume Cannabis When They’re Not On The Clock
New Jersey cops can consume cannabis without penalty while off the job. The message came via a memo from acting New Jersey Attorney General Matthew Platkin to police chiefs telling them that they “may not take any adverse action against any officers because they do or do not use cannabis off duty.”
It’s Official: New Jersey Cannabis Sales To Begin April 21, Why Not 4/20? Here’s Why
New Jersey legal weed sales can begin April 21, state officials announced. The state Cannabis Regulatory Commission will issue licenses to seven medical marijuana dispensaries, officially known as alternative treatment centers that will also sell recreational weed beginning on April 21.
New Jersey Cannabis Sales Expected To Begin Soon As Panel Takes Historic Vote
New Jersey's long-awaited launch of its recreational cannabis market just got the green light. Regulators agreed that seven medical marijuana shops will be allowed to begin sales, possibly within weeks, after a series of disappointing setbacks and 17 months since cannabis was legalized at the ballot box in a referendum.
Cannabis M&A Activity On Fire: But Is It What Was Expected? Experts Say, Look At Q1 Earnings
Consolidation of the cannabis industry is inevitable as the market matures.
Heading into 2022, numerous forecasts predicted another flurry of M&A activity after an energized 2021. With nearly three months of the year complete, opinions are split on M&A activity so far.
Analyst On Cresco’s Deal With Columbia Care And Earnings Results For Q4 2021
The Analyst:
Pablo Zuanic, from Cantor Fitzgerald, rated Cresco Labs, Inc. (OTC: CRLBF) as Overweight with a price target of $19.00.